Pediatricians told not to use nasal flu vaccine this year

Ahead of flu season, the American Academy of Pediatrics has released its recommendations for using vaccines and antiviral medications for flu prevention, and nasal spray vaccines aren’t part of its plan.

The AAP guidelines referenced the recommendations from the CDC, which said in July that the FluMist nasal spray vaccine wouldn’t work for the 2016-17 flu season. Its effectiveness rate was 3 percent among children between the ages of 2 and 17, compared to 63 percent for the traditional injected vaccine.

This recommendation could affect how much of the vaccine is available.

“Without an intranasal influenza vaccine recommended for this 2016–2017 season, the AAP is working closely with manufacturers to make available an adequate supply with geographically wide and timely distribution of inactivated vaccine products for pediatric-aged patients,” the recommendation said.

The AAP went on to say pediatricians can boost acceptance of the vaccine—which has become a problem for many physicians—by explaining its importance for children, emphasizing when a second dose is needed and explaining why the nasal spray version isn’t available.

It’s recommended providers start offering the vaccine no later than October to get patients immunized early, and may continue offering it until June 30. All patients older than six months should be vaccinated, according to the AAP.

According to CDC data, 85 pediatric deaths associated with the flu were confirmed in the 2015-2016 flu season, with nearly 60 percent of those patients indicating no other high-risk underlying condition. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year.